Navigation Links
Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Micrus Endovascular Corporation
Date:10/4/2007

BENSALEM, Pa., Oct. 4 /PRNewswire/ -- Law Offices of Howard G. Smith announces that a securities class action lawsuit has been filed on behalf of shareholders who purchased the common stock of Micrus Endovascular Corporation ("Micrus" or the "Company")(Nasdaq: MEND) between February 12, 2007 and September 17, 2007, inclusive (the "Class Period"). The class action lawsuit was filed in the United States District Court for the Southern District of Florida.

The Complaint alleges that defendants violated federal securities laws by issuing material misrepresentations to the market concerning the Company's business and prospects, thereby artificially inflating the price of Micrus securities.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased Micrus shares between February 12, 2007 and September 17, 2007, you have certain rights, and have until December 3, 2007, to move for Lead Plaintiff status. To be a member of the class you need not take any action at this time, and you may retain counsel of your choice. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215)638-4847, Toll-Free at (888)638-4847, by email to howardsmithlaw@hotmail.com or visit our website at http://www.howardsmithlaw.com.


'/>"/>
SOURCE Law Offices of Howard G. Smith
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Gigantic Effort: Smoking To Be Banned in British Telecom’s Offices and Van
2. Smoking to be Prohibited at Public Offices in Bangkok from 2008
3. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
4. Iodex goes to SmithKline Beecham consumer Healthcare
5. GlaxoSmithKline To Cultivate Non-Smoking Environment
6. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
7. FDA Mislead On Asthma Drug By GlaxoSmithKline
8. GlaxoSmithKline Defends Its Products
9. GlaxoSmithKline launches diabetes and cancer drugs
10. Generic Products Compete With GlaxoSmithKline
11. New Cervical Cancer Vaccine to Be Launched By Glaxo Smithkline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Basketball is a game for everyone, not ... Peety PoppersTM series, sign language translation is featured in the top right of the ... Peety PoppersTM lessons has a sign language translator to teach kids the game and ...
(Date:2/11/2016)... ... February 12, 2016 , ... Fitbody Personal Training offers outdoor training ... exciting way to get fit and healthy. Located in Phoenixville, PA, the classes are ... class designed for horseback riders who want to lose weight and tone up. This ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... participated in the American Osteopathic Association’s (AOA) Match Program Tuesday, February 9, taking ... Program places students into osteopathic graduate medical education positions across the country. Of ...
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of ... from 0.416 in 2013. The SJR uses data taken from the Scopus database (Elsevier ... the number of citations received by the journal over a three year period and ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... diabetes has been gearing up for their simultaneous grand openings in March. All ... right now that you’re probably wondering, is reversing diabetes possible? According to this ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
(Date:2/11/2016)... 11, 2016 The primary goal of this ... patterns on the usage of liquid biopsy. Key information ... - Timeframe of liquid biopsy adoption amidst future ... Evs—by organization type - Sample inflow to conduct liquid ... stool, serum, and so on. - Correlation analysis of ...
Breaking Medicine Technology: